Description
Elifor (Desvenlafaxine Succinate) Tablets with Prolonged Release 50 mg. №28
Ingredients
Active ingredient: Desvenlafaxine succinate. Inactive ingredients: Mannitol, hypromellose, ethylcellulose, and other excipients.
Mechanism of Action
Desvenlafaxine succinate, a serotonin-norepinephrine reuptake inhibitor (SNRI), acts by inhibiting the reuptake of serotonin and norepinephrine in the brain, thereby restoring the balance of these neurotransmitters and alleviating symptoms of depression.
Pharmacological Properties
Desvenlafaxine succinate prolongs the effects of serotonin and norepinephrine, leading to improved mood and reduced depressive symptoms in patients with major depressive disorder.
Indications for Use
Elifor tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
Contraindications
Do not use Elifor tablets if you are allergic to desvenlafaxine or if you have taken any monoamine oxidase inhibitors (MAOIs) within the last 14 days.
Side Effects
Common side effects of Elifor tablets may include nausea, dizziness, insomnia, and headache. Contact your healthcare provider if you experience severe side effects or allergic reactions.
Usage Instructions
Recommended dosage: 50 mg once daily, with or without food. Swallow the tablet whole with water; do not crush or chew. Follow your healthcare provider’s instructions carefully and do not discontinue the medication abruptly.
Benefits Compared to Analogues
Elifor tablets offer the advantage of prolonged release formulation, providing steady levels of desvenlafaxine in the body and potentially improving treatment adherence compared to immediate-release formulations.
Suitable Patient Groups
Elifor tablets are suitable for adult patients with major depressive disorder. Dosage adjustments may be necessary for elderly patients or those with hepatic or renal impairment.
Storage Conditions and Shelf Life
Store Elifor tablets at room temperature, away from moisture and heat. Check the expiration date on the packaging and do not use the tablets beyond the indicated shelf life.
Packaging Description
Each package of Elifor tablets contains 28 tablets of 50 mg desvenlafaxine succinate with prolonged release formulation.
Clinical Evidence and Proven Effectiveness
Pharmacological Effects: Desvenlafaxine succinate acts by inhibiting the reuptake of serotonin and norepinephrine, thereby prolonging the effects of these neurotransmitters in the brain. This mechanism helps alleviate symptoms of depression and improve mood.
Clinical Trials: Clinical studies have demonstrated the efficacy of desvenlafaxine in the treatment of major depressive disorder. In a randomized controlled trial published in the Journal of Clinical Psychiatry, desvenlafaxine was found to be significantly more effective than a placebo in reducing depressive symptoms.
